Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Genetics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Multiple Sclerosis and Neuroimmunology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Biostatistics and Epidemiology, Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran
P.O. BOX: 8174673461
Department of Immunology
Faculty of Medicine
Isfahan University of Medical
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Semaphorin-3A as An Immune Modulator Is Suppressed
by MicroRNA-145-5p .
Semaphorin-3A (SEMA3A) and its receptors are found on some immune cells and act as suppressors of
immune cells over-activation. Considering the role of SEMA3A and its down-regulation in some autoimmune diseases,
as well as our bioinformatics predictions, we assumed that miR-145-5p might affect SEMA3A expression. So, we aimed
to determine the effect of miR-145-5p on SEMA3A gene expression level.
Materials and Methods
In this experimental study, we evaluated the effect of miR-145-5p transfection on SEMA3A
expression in peripheral blood mononuclear cells (PBMCs) using ELISA and quantitative real-time polymerase chain
reaction (PCR) methods.
Our results showed that miR-145-5p is able to decrease SEMA3A expression at both protein and mRNA levels.
These data confirmed our previous bioinformatic prediction about the inhibitory effect of miR-145-5p on SEMA3A expression.
These results enlightened us about an unknown aspect of SEMA3A role in some autoimmune disorders
like multiple sclerosis (MS) and rheumatoid arthritis (RA) and also proposed SEMA3A as a potential therapeutic approach.